AEON Biopharma, Inc. (NASDAQ:AEON) Director Acquires $25,000.00 in Stock

AEON Biopharma, Inc. (NASDAQ:AEON) Director Jost Fischer bought 50,000 shares of the business’s stock in a transaction that occurred on Monday, May 19th. The shares were bought at an average cost of $0.50 per share, for a total transaction of $25,000.00. Following the completion of the purchase, the director now owns 146,785 shares of the company’s stock, valued at $73,392.50. This represents a 51.66% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Jost Fischer also recently made the following trade(s):

• On Tuesday, May 20th, Jost Fischer purchased 60,000 shares of AEON Biopharma stock. The stock was acquired at an average cost of $0.51 per share, with a total value of $30,600.00.

AEON Biopharma Stock Down 2.7%

AEON stock opened at $0.53 on Friday. The firm has a market capitalization of $5.62 million, a PE ratio of 2.97 and a beta of 0.38. The stock’s 50 day moving average is $0.50 and its 200-day moving average is $16.17. AEON Biopharma, Inc. has a twelve month low of $0.38 and a twelve month high of $269.28.

Institutional Trading of AEON Biopharma

A hedge fund recently bought a new stake in AEON Biopharma stock. Dauntless Investment Group LLC bought a new stake in AEON Biopharma, Inc. (NASDAQ:AEON) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,025,000 shares of the company’s stock, valued at approximately $594,000. AEON Biopharma makes up approximately 0.7% of Dauntless Investment Group LLC’s portfolio, making the stock its 18th largest position. Dauntless Investment Group LLC owned about 9.73% of AEON Biopharma at the end of the most recent quarter. Institutional investors own 22.78% of the company’s stock.

About AEON Biopharma

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder.